Overview

A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation

Status:
Completed

Trial end date:
1998-10-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to assess the effectiveness and safety of an oral solution of risperidone (an antipsychotic medication) versus placebo in the treatment of conduct disorder in children with mild, moderate, or borderline mental retardation.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen Pharmaceutica N.V., Belgium

Treatments:

Risperidone